News

The treatment was shown to reduce the frequency of bone fracture across the most common osteoporotic fracture sites. Reclast was highly effective in reducing the incidence of bone

The patents on the drug are due to expire at the end of 2007, which will allow the biopharmaceutical company to develop generic Taxotere, which generated worldwide sales

In what is described as the largest diabetes-prevention trial ever conducted, Avandia (rosiglitazone) reduced the risk of developing type 2 diabetes by 62% relative to placebo among people

The companies are collaborating to develop and commercialize Schering's novel selective estrogen receptor downregulator (SERD,) for the treatment of breast cancer. AstraZeneca – which is looking to rebuild

Dr Agop Bedikian, the lead author on the paper, said: “This was the first trial to achieve such a broad array of positive endpoints. I believe the aggregate

Single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunteers and in a clinically and statistically significant increase in red blood cells and

The company said that it plans to assess whether there is an opportunity to continue development of CTI-01 with a collaborative partner or to out-license the drug. Critical

A research group headed by James Morre, professor of medicinal chemistry at Purdue University, obtained results supporting that Phenoxodiol specifically targets a protein on prostate cancer cells known

SCV-07 works by stimulating the immune system through its effects on T-helper 1 cells, which are essential for clearance of viral infections. The trial found the treatment to